Bullish indicating open at $55-$60, IPO prices at $37
TG Therapeutics Inc . (NASDAQ:TGTX) stock has reached a remarkable 52-week high, touching $40.32 amidst a flurry of investor optimism. With a market capitalization of $5.8 billion and impressive gross profit margins of 88.3%, the company has caught the attention of market analysts. According to InvestingPro analysis, the stock is currently trading slightly above its Fair Value. This peak represents a significant milestone for the biopharmaceutical company, which has seen its shares skyrocket over the past year. The impressive ascent is underscored by strong financial performance, with revenue growth of 40.8% and a healthy current ratio of 6.25. The company’s robust performance has driven a remarkable 141% return over the past year. InvestingPro offers 18 additional investment tips for TGTX, available with a subscription. Investors are closely monitoring TG Therapeutics as it continues to make waves in the industry, with many attributing the stock’s performance to the company’s promising developments in novel treatments for B-cell malignancies and autoimmune diseases. For deeper insights into TGTX’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, TG Therapeutics has reported impressive financial results for the fourth quarter of 2024, exceeding analyst expectations with a GAAP earnings per share (EPS) of $0.15, compared to the projected $0.08. The company’s revenue for the quarter reached $108.19 million, surpassing the consensus estimate of $97.66 million, marking a significant year-over-year growth. TG Therapeutics’ full-year revenue for 2024 was $329 million, with $310 million coming from net sales of Briumvi in the U.S. and additional revenue from international sales through its partner, Neuraxpharm.
H.C. Wainwright has maintained a Buy rating for TG Therapeutics, setting a price target of $55 based on the company’s strong financial performance and future revenue projections. The firm anticipates a total revenue of $539.9 million for 2025, with a GAAP EPS of $1.19. Cantor Fitzgerald also reiterated an Overweight rating, expressing optimism about the potential upside for Briumvi’s 2025 revenue guidance, which is projected at $525 million in the U.S. market.
The company’s management highlighted strong market uptake for Briumvi, with January and February showing the highest new patient enrollments since the drug’s launch. Additionally, TG Therapeutics has expanded Briumvi’s patent protection through 2042 and is exploring further development opportunities, including a subcutaneous formulation. These developments suggest a robust commercial performance and promising financial outlook for TG Therapeutics in the upcoming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.